Patent agreement reached for mRNA vaccines between CureVac and GSK and Pfizer-BioNTech
A legal dispute that lasted years in the field of mRNA technologies, which played a key role in the fight against COVID-19, ended with an agreement between the main pharmaceutical groups involved. Germany’s CureVac and Britain’s GSK have in fact reached an...
